Diabetes & Nutritional Science Division, Kings College London, Franklin-Wilkins Building, London, UK.
Heart. 2013 Sep;99(17):1256-60. doi: 10.1136/heartjnl-2013-303688. Epub 2013 Jun 13.
The effectiveness of salt restriction to lower blood pressure (BP) in Bangladeshi patients with chronic kidney disease (CKD) is uncertain.
To test the hypothesis that a tailored intervention intended to reduce salt intake in addition to standard care will achieve a greater reduction in BP in UK Bangladeshi patients with CKD than standard care alone.
A randomised parallel-group controlled trial conducted over a 6 month period.
A tertiary renal unit based in acute care hospital in East London.
56 adult participants of Bangladeshi origin with CKD and BP >130/80 mm Hg or on antihypertensive medication.
Participants were randomly allocated to receive a tailored low-salt diet or the standard low-salt advice. BP medication, physical activity and weight were monitored.
The primary outcome was change in ambulatory BP. Adherence to dietary advice was assessed by measurement of 24 h urinary salt excretion.
Of 56 participants randomised, six withdrew at the start of the study. During the study, one intervention group participant died, one control group participant moved to Bangladesh. Data were available for the primary endpoint on 48 participants. Compared with control group the intervention urinary sodium excretion fell from 260 mmol/d to 103 mmol/d (-131 to -76, p<0.001) at 6 months and resulted in mean (95% CI) falls in 24 h systolic/diastolic BP of -8 mm Hg (-11 to -5)/2 (-4 to -2) both p<0.001.
A tailored intervention can achieve moderate salt restriction in patients with CKD, resulting in clinically meaningful falls in BP independent of hypertensive medication.
ClinicalTrials.gov NCT00702312.
盐限制对降低孟加拉国慢性肾脏病(CKD)患者血压(BP)的有效性尚不确定。
检验以下假设,即除标准护理外,还专门针对减少盐摄入量的干预措施将比单独的标准护理更能降低英国孟加拉国 CKD 患者的血压。
一项为期 6 个月的随机平行组对照试验。
东伦敦急性保健医院的三级肾脏科。
56 名成年孟加拉裔 CKD 患者,血压>130/80mmHg 或正在服用降压药物。
参与者被随机分配接受量身定制的低盐饮食或标准低盐建议。监测血压药物、体力活动和体重。
主要结果是动态血压的变化。通过测量 24 小时尿盐排泄量来评估饮食建议的依从性。
在 56 名随机分配的参与者中,有 6 名在研究开始时退出。在研究过程中,1 名干预组参与者死亡,1 名对照组参与者搬回孟加拉国。有 48 名参与者的数据可用于主要终点。与对照组相比,干预组尿钠排泄量从 260mmol/d 下降到 103mmol/d(-131 至-76,p<0.001),6 个月时平均(95%CI)24 小时收缩压/舒张压分别下降 8mmHg(-11 至-5)/2mmHg(-4 至-2),均 p<0.001。
量身定制的干预措施可以使 CKD 患者实现适度的盐限制,从而导致血压有临床意义的下降,而与降压药物无关。
ClinicalTrials.gov NCT00702312。